Hohenberger P, Haier J, Schlag P M
Division of Surgery and Surgical Oncology, Robert-Rössle Hospital and Tumor Institute, Max-Delbrück Center for Molecular Medicine, Virchow Klinikum, Humboldt University of Berlin, Germany.
Eur J Cancer. 1997 Apr;33(4):596-601. doi: 10.1016/s0959-8049(97)00013-0.
The aim of this study was to monitor serum and perfusate levels of myoglobin (MB) and creatine kinase (CK) during isolated limb perfusion (ILP) in order to identify those at risk of renal failure. We investigated the release of MB and CK in 40 patients who underwent ILP for melanoma (n = 15) or sarcoma (n = 25) using rhTNF alpha/melphalan (n = 28) or a triple-drug regimen (n = 12). Serial determinations of CK and MB were performed in both perfusate and systemic circulation during and after ILP and renal function was assessed. A significant increase of MB could be detected in the perfusate during ILP. After ILP, an up to 100-fold increase with a double peak of MB at 4 h and 24 h postoperatively was observed. The maximum elevation of serum activity of CK was at 30 h. The increase for both proteins was highly significant (P < 0.001). ILP with rhTNF alpha/melphalan yielded significantly (P < 0.001) higher serum values of MB and CK and also the impairment of the renal function was more pronounced. The peak values of MB after ILP occur early and allow the patients most at risk of developing renal failure to be identified. Rhabdomyolysis can be detected early by determination of MB from the perfusate. Further measurements twice daily for 2-3 days post ILP from serum samples as well as daily assessment of MB in the urine is helpful for detecting myoglobinuria and imminent renal failure.
本研究的目的是监测在离体肢体灌注(ILP)过程中肌红蛋白(MB)和肌酸激酶(CK)的血清及灌注液水平,以确定有肾衰竭风险的患者。我们调查了40例行ILP治疗黑色素瘤(n = 15)或肉瘤(n = 25)的患者中MB和CK的释放情况,这些患者使用了重组人肿瘤坏死因子α/美法仑(n = 28)或三联药物方案(n = 12)。在ILP期间及之后,对灌注液和体循环中的CK和MB进行了连续测定,并评估了肾功能。在ILP期间,灌注液中可检测到MB显著增加。ILP后,观察到术后4小时和24小时MB增加高达100倍,出现双峰。CK血清活性的最大升高出现在30小时。两种蛋白的增加均非常显著(P < 0.001)。使用重组人肿瘤坏死因子α/美法仑进行ILP产生的MB和CK血清值显著更高(P < 0.001),肾功能损害也更明显。ILP后MB的峰值出现较早,能够识别出发生肾衰竭风险最高的患者。通过测定灌注液中的MB可早期检测到横纹肌溶解。ILP后2 - 3天每天两次从血清样本中进一步测量,以及每天评估尿液中的MB,有助于检测肌红蛋白尿和即将发生的肾衰竭。